Sugi Predict

Sugi Predict / Compounds / SCHEMBL25895293

SCHEMBL25895293

SCHEMBL25895293

CC(C)C(=O)N1CCN(C(=O)N(C)C(C)C)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRNB2 P17787 1/20 0.38
▸ CHRNA3 P32297 1/20 0.38
▸ CHRNA4 P43681 1/20 0.38
▸ CHRNB3 Q05901 1/20 0.38
▸ CHRNA6 Q15825 1/20 0.38
▸ PKM P14618 1/20 0.38
▸ MAPT P10636 1/20 0.36
▸ MET P08581 1/20 0.35
▸ HTR1A P08908 1/20 0.34
▸ ALDH1A1 P00352 3/20 0.34
▸ TSHR P16473 3/20 0.34
▸ LMNA P02545 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ MTNR1B P49286 1/20 0.33
▸ GLA P06280 1/20 0.33
▸ NAMPT P43490 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33
▸ POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25895218 0.94 PKM (0.35) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL1911532 0.83 MAPT (0.52) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL4546617 0.82 CHRNB2 (0.50) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL22753493 0.82 CHRNB2 (0.50) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL674660 0.82 — —
SCHEMBL12872504 0.81 HTR1A (0.53) MAPTHTR1AALDH1A1TSHRLMNA
SCHEMBL14319076 0.80 SMN1; SMN2 (0.39) MAPTALDH1A1TSHRSMN1; SMN2MEN1
SCHEMBL20346243 0.79 HRH3 (0.44) MAPT
SCHEMBL23342005 0.76 MAPT (0.34) MAPTHTR1AALDH1A1SMN1; SMN2MEN1
SCHEMBL22152624 0.76 KDM4E (0.44) HTR1AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230374035-A1 RAS INHIBITORS Revolution Medicines, Inc. 2023-11-23 — — US disclosed
US-11739074-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2023-08-29 — — US disclosed
US-20230233569-A1 METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-07-27 — — US disclosed
US-20230233569-A1 METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-07-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11739074-B2 Ras inhibitors KRAS, NRAS, HRAS CHRNB2 4850/4885CHRNA3 4873/4885CHRNA4 4883/4885
US-20230233569-A1 METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS KRAS, HRAS, MTOR CHRNB2 4837/4885CHRNA3 4859/4885CHRNA4 4874/4885
US-20230374035-A1 RAS INHIBITORS KRAS, NRAS, HRAS CHRNB2 4838/4885CHRNA3 4860/4885CHRNA4 4878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.